Survival benefit with concomitant clopidogrel and glycoprotein IIb/IIIa inhibitor therapy at ad hoc percutaneous coronary intervention

Mayo Clinic Proceedings

Volumn 83, Issue 9, 2008, Pages 995-1001

  Gumina, Richard J ^a   Yang, Eric H ^b   Sandhu, Gurpreet S ^c   Prasad, Abhiram ^c   Bresnahan, John F ^c   Lennon, Ryan J ^c   Rihal, Charanjit S ^c   Holmes Jr , David R ^c   Singh, Mandeep ^c  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; FIBRINOGEN RECEPTOR;

AGED; ANGIOGRAPHY; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION;

EID: 51349158052     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/83.9.995     Document Type: Article

References (26)

1. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330(14):956-961.
2. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336(24):1689-1696.
3. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352(9122):87-92.
4. O'Shea JC, Hafley GE, Greenberg S, et al; ESPRIT Investigators. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA. 2001;285(19):2468-2473.
5. Kastrati A, Mehilli J, Schuhlen H, et al, Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment (ISAR-REACT) Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med. 2004;350(3):232-238.
6. Kandzari DE, Berger PB, Kastrati A, et al, ISAR-REACT Study Investigators. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol. 2004;44(11):2133-2136.
7. Claeys MJ, Van der Planken MG, Bosmans JM, et al. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? a focus on peri-procedural myonecrosis. Eur Heart J. 2005 Mar;26(6):567-575. Epub 2004 Dec 16.
8. Schomig A, Schmitt C, Dibra A, et al, Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. Eur Heart J. 2005 Jul;26(14):1379-1384. Epub 2005 Feb 25.
9. Blankenship JC, Klein LW, Laskey WK, et al. SCAI statement on ad hoc versus the separate performance of diagnostic cardiac catheterization and coronary intervention. Catheter Cardiovasc Interv. 2004;63(4):444-451.
10. Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol. 2002;40(2):231-237.
11. Kapetanakis EI, Medlam DA, Boyce SW, et al. Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache? Eur Heart J. 2005 Mar;26(6):576-583. Epub 2005 Feb 21.
12. Chu MW, Wilson SR, Novick RJ, Stitt LW, Quantz MA. Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg. 2004;78(5):1536-1541.
13. Gurbel PA, Samara WM, Bliden KP. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Platelets. 2004;15(2):95-99.
14. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55.
15. Vorchheimer DA, Badimon JJ, Fuster V. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. JAMA. 1999;281(15):1407-1414.
16. Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol. 2003;41(1):26-32.
17. Kong DF, Hasselblad V, Harrington RA, et al. Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol. 2003;92(6):651-655.
18. Steinhubl SR, Berger PB, Mann JT III, et al; CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial [published correction appears in JAMA. 2003;289(8):987]. JAMA. 2002;288(19):2411-2420.
19. van der Heijden DJ, Westendorp IC, Riezebos RK, et al. Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation. J Am Coll Cardiol. 2004;44(1):20-24.
20. Mehta SR, Yusuf S, Peters RJ, et al; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527-533.
21. Ernst NM, Suryapranata H, Miedema K, et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004;44(6):1187-1193.
22. Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement [letter]. Heart. 2001;85(1):92-93.
23. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation. 2005 Mar 8;111(9):1153-1159. Epub 2005 Feb 28.
24. Raveendran G, Ting HH, Best PJ, et al. Eptifibatide vs abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute myocardial infarction. Mayo Clin Proc. 2007;82(2):196-202.
25. Lincoff AM, Bittl JA, Harrington RA, et al; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial [published correction appears in JAMA. 2003;289(13):1638]. JAMA. 2003;289(7):853-863.
26. Lincoff AM, Kleiman NS, Kereiakes DJ, et al; REPLACE-2 Investigators. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial [published correction appears in JAMA. 2006;296(1):46]. JAMA. 2004;292(6):696-703.